FDA Commissioner Scott Gottlieb, MD, has issued a statement on the steps being taken to promote development of generic versions of opioids formulated to deter abuse. “As we continue to confront the staggering human and economic toll created by opioid abuse and addiction, we’re focused on taking actions that reduce the scope of new addiction by decreasing unnecessary exposure to opioids. At the same time, we also must take steps to help those with acute and chronic pain who need access to medicines, including opioids, get access to improved alternatives…”

Read Full Statement